Status:
COMPLETED
Canadian National PDA Treatment Study
Lead Sponsor:
IWK Health Centre
Collaborating Sponsors:
Provincial Health Services Authority British Columbia
Children's Hospital of Eastern Ontario
Conditions:
Patent Ductus Arteriosus
Extreme Prematurity
Eligibility:
All Genders
Up to 12 years
Brief Summary
Patent ductus arteriosus (PDA) is the most common cardiovascular problem that develops in preterm infants. Persistent PDA may result in higher rates of death, chronic lung disease (CLD), pulmonary hem...
Detailed Description
In this study, we intend to generate real-world evidence (RWE) by analyzing real-world data (RWD) (defined as data generated during routine clinical practice) from a registry-based Comparative Effecti...
Eligibility Criteria
Inclusion
- Extremely preterm infants (\<29 weeks gestational age) with an echocardiography confirmed PDA who will be treated according to attending team
Exclusion
- Any infant who received pharmacotherapy for a clinically symptomatic PDA without prior echocardiographic confirmation of the presence of PDA will be excluded from all analyses.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
1663 Patients enrolled
Trial Details
Trial ID
NCT04347720
Start Date
January 1 2020
End Date
December 31 2023
Last Update
June 21 2024
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
Foothills Medical Centre
Calgary, Alberta, Canada
2
Royal Alexandra Hospital
Edmonton, Alberta, Canada
3
Royal Columbian Hospital
New Westminster, British Columbia, Canada
4
British Columbia Women's Hospital
Vancouver, British Columbia, Canada